Market Overview:
The global hemophilia A and B therapeutics materials market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of hemophilia A and B, rising awareness about hemophilia treatments, and technological advancements in the field of hemophilia treatment. Hemophiliacs are at an increased risk for developing inhibitors against replacement therapies, which is a major challenge for manufacturers of these therapies. Inhibitors are antibodies that develop in some patients after repeated exposure to clotting factor concentrates derived from human blood or plasma. They can lead to life-threatening complications by blocking the action of clotting factors needed for effective hemostasis (the process that stops bleeding). Based on type, desmopressin held a dominant share in 2017 and is expected to maintain its dominance during the forecast period as well. This can be attributed to its high efficacy as compared to other types available in the market.
Product Definition:
Hemophillia A and B Therapeutics Materials are used to help people with hemophillia. Hemophillia is a disorder that causes someone to bleed too much. The hemophillia therapies work by helping the blood clot better so that there is less bleeding.
Desmopressin:
Desmopressin is a drug that reduces the amount of blood loss during and after bleeding. It is used to treat two types of hemophilia, namely A and B. Hemophilia A occurs when there is less than 2% of normal clotting factor in the body, while hemophilia B occurs when there is no functional coagulation protein in the body.
Octocogalfa:
Introduction: Octocogalfa (OCT) is a synthetic analog of human coagulation factor II. OCT has been reported to be effective in the treatment of hereditary hemophilia A and B, which are caused by deficiency of coagulation factor in blood. OCT promotes the production of normal clotting factors as well as helps repair damaged ones, thus promoting bleeding control.
Application Insights:
Based on application, the global market is segmented into dental clinics, hospitals and ambulatory surgical centers. The hospital segment dominated the overall market in terms of revenue in 2017. Hemophillia products are used to treat a variety of conditions associated with blood loss such as low platelet count, slow wound healing and increased risk of infection. As a result, increasing number of patients undergoing surgery has led to an increase in demand for hemopressin therapy materials at hospitals across the world.
The dental clinic segment is expected to witness lucrative growth over the forecast period owing to rising awareness about oral health care among consumers globally coupled with growing incidences of hemophilia among baby boomers and generation X parents worldwide due primarily to high prevalence rates during pre-pubertal years (0-8 years) across various regions including North America & Europe which may lead towards higher usage rate during this age group which will eventually drive product demand at this location over next few years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key manufacturers and well-established healthcare infrastructure are some factors responsible for its large share. In addition, increasing prevalence of rare disorders such as hematological malignancy is expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare facilities & infrastructure, and growing awareness among patients about advanced therapies in this region. Moreover, increasing investments by governments and private firms for developing innovative products with reduced side effects will boost revenue generation in APAC region over next eight years. For instance, Novo Nordisk has invested around USD X million per year on R&D pertaining to diabetes care products till 2016; however it increased its investment spending on Hemophilia treatment since then (USD X million per year).
Growth Factors:
- Increasing incidence of hemophilia A and B across the globe
- Growing demand for better quality and innovative therapeutics materials products
- Rising number of research and development activities in hemophilia A and B therapeutics materials market
- Technological advancements in hemophilia A and B therapeutics materials market
- Emergence of novel therapies for treatment of hemophilia A and B
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemophillia A and B Therapeutics Materials Market Research Report
By Type
Desmopressin, Octocogalfa, Nonacogalfa, Others
By Application
Dental Clinics, Hospitals, Ambulatory Surgical Centers
By Companies
Arsia therapeutics, Spark Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Sangamo Therapeutics, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Hemophillia A and B Therapeutics Materials Market Report Segments:
The global Hemophillia A and B Therapeutics Materials market is segmented on the basis of:
Types
Desmopressin, Octocogalfa, Nonacogalfa, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Dental Clinics, Hospitals, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Arsia therapeutics
- Spark Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Sangamo Therapeutics, Inc.
Highlights of The Hemophillia A and B Therapeutics Materials Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Desmopressin
- Octocogalfa
- Nonacogalfa
- Others
- By Application:
- Dental Clinics
- Hospitals
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemophillia A and B Therapeutics Materials Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemophillia A and B Therapeutics Materials are a set of medical supplies used to treat people with hemophilia. These supplies include medications, infusion devices, and other equipment necessary to help patients manage their condition. Hemophillia A and B Therapeutics Materials also include information about the disease and how it is treated.
Some of the key players operating in the hemophillia a and b therapeutics materials market are Arsia therapeutics, Spark Therapeutics, Inc., Alnylam Pharmaceuticals, Inc., Sangamo Therapeutics, Inc..
The hemophillia a and b therapeutics materials market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hemophillia A and B Therapeutics Materials Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hemophillia A and B Therapeutics Materials Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hemophillia A and B Therapeutics Materials Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hemophillia A and B Therapeutics Materials Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hemophillia A and B Therapeutics Materials Market Size & Forecast, 2020-2028
4.5.1 Hemophillia A and B Therapeutics Materials Market Size and Y-o-Y Growth
4.5.2 Hemophillia A and B Therapeutics Materials Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Desmopressin
5.2.2 Octocogalfa
5.2.3 Nonacogalfa
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Dental Clinics
6.2.2 Hospitals
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hemophillia A and B Therapeutics Materials Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hemophillia A and B Therapeutics Materials Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Desmopressin
9.6.2 Octocogalfa
9.6.3 Nonacogalfa
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Dental Clinics
9.10.2 Hospitals
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Desmopressin
10.6.2 Octocogalfa
10.6.3 Nonacogalfa
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Dental Clinics
10.10.2 Hospitals
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Desmopressin
11.6.2 Octocogalfa
11.6.3 Nonacogalfa
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Dental Clinics
11.10.2 Hospitals
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Desmopressin
12.6.2 Octocogalfa
12.6.3 Nonacogalfa
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Dental Clinics
12.10.2 Hospitals
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Desmopressin
13.6.2 Octocogalfa
13.6.3 Nonacogalfa
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Dental Clinics
13.10.2 Hospitals
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hemophillia A and B Therapeutics Materials Market: Competitive Dashboard
14.2 Global Hemophillia A and B Therapeutics Materials Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Arsia therapeutics
14.3.2 Spark Therapeutics, Inc.
14.3.3 Alnylam Pharmaceuticals, Inc.
14.3.4 Sangamo Therapeutics, Inc.
